Skip to main content
. Author manuscript; available in PMC: 2010 Jun 14.
Published in final edited form as: Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–580. doi: 10.1615/critrevtherdrugcarriersyst.v26.i6.10

FIGURE 6.

FIGURE 6

A, Targeting pathways of lipid-based nanoparticles to tumors. Schematic presentation of nanoparticles that passively or actively target tumors. These particles accumulate in the tumor area due to the leaky vasculature surrounding the tumors. However, targeted nanoparticles bind to the target tumor cells via ligand-receptor interactions and are internalized, whereas non-targeted nanoparticles are less efficient in interacting with tumor cells. B, Antibodies and antibody fragments used for targeting of lipid-based nanoparticles.